Moderna on Wednesday said it has begun submitting data to the Food and Drug Administration (FDA) about a booster dose of its COVID-19 vaccine.<\/p>\n
The data submitted is for the use of a booster dose of its authorized two-shot vaccine at the 50 microgram dose, the company said.<\/p>\n
The company said neutralizing antibodies had waned “significantly” prior to boosting approximately six months after the second dose.<\/p>\n
The Biden administration announced last month that boosters would be available the week of Sept. 20 to most people fully vaccinated eight months earlier.<\/p>\n
Context:\u00a0<\/strong>The announcement comes after the U.S. authorized third doses of both Moderna and Pfizer’s COVID-19 vaccines for immunocompromised people last month, but boosters for the general public are not yet authorized.<\/p>\n More than 1 million people have since received a third dose according to the Centers for Disease Control and Prevention, though the agency does not distinguish if the people were immunocompromised.<\/p>\n